Literature DB >> 14532138

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

D E Furst1, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, M Dougados, P Emery, A Gibofsky, A F Kavanaugh, E C Keystone, L Klareskog, A S Russell, L B A van de Putte, M H Weisman, A F Kavenaugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14532138      PMCID： PMC1766759          DOI： 10.1136/ard.62.suppl_2.ii2

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  48 in total

1.  Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents.

Authors:  D E Furst; J Cush; S Kaufmann; J Siegel; R Kurth
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

2.  Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Authors:  Jong-Hoon Lee; Nancy R Slifman; Sharon K Gershon; Evelyne T Edwards; William D Schwieterman; Jeffrey N Siegel; Robert P Wise; S Lori Brown; John N Udall; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-10

3.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.

Authors:  Stefan D Anker; Andrew J S Coats
Journal:  Int J Cardiol       Date:  2002-12       Impact factor: 4.164

4.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors:  Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

5.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Stanley Cohen; Eric Hurd; John Cush; Michael Schiff; Michael E Weinblatt; Larry W Moreland; Joel Kremer; Moraye B Bear; William J Rich; Dorothy McCabe
Journal:  Arthritis Rheum       Date:  2002-03

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Authors:  Nancy R Slifman; Sharon K Gershon; Jong-Hoon Lee; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2003-02

8.  [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].

Authors:  O Brocq; Y Plubel; V Breuil; C Grisot; P Flory; A Mousnier; L Euller-Ziegler
Journal:  Presse Med       Date:  2002-11-23       Impact factor: 1.228

9.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

Authors:  Mark C Genovese; Joan M Bathon; Richard W Martin; Roy M Fleischmann; John R Tesser; Michael H Schiff; Edward C Keystone; Mary Chester Wasko; Larry W Moreland; Arthur L Weaver; Joseph Markenson; Grant W Cannon; George Spencer-Green; Barbara K Finck
Journal:  Arthritis Rheum       Date:  2002-06

10.  Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.

Authors:  Daniel J Lovell; Edward H Giannini; Andreas Reiff; Olcay Y Jones; Rayfel Schneider; Judyann C Olson; Leonard D Stein; Abraham Gedalia; Norman T Ilowite; Carol A Wallace; Mary Lange; Barbara K Finck; Daniel J Burge
Journal:  Arthritis Rheum       Date:  2003-01
View more
  18 in total

1.  TNF-alpha antagonist therapy modify the tuberculin skin test response.

Authors:  Tulin Cagatay; Zeki Kilicaslan; Penbe Cagatay; Munevver Mertsoylu; Ziya Gulbaran; Reyhan Yildiz; Leyla Pur; Sevil Kamali; Ahmet Gul
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

2.  [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].

Authors:  U Müller-Ladner
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

3.  Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?

Authors:  B E Joven; R Almodóvar; M Galindo; I Mateo; J L Pablos
Journal:  Ann Rheum Dis       Date:  2006-05       Impact factor: 19.103

4.  Gene transfer to human joints: progress toward a gene therapy of arthritis.

Authors:  Christopher H Evans; Paul D Robbins; Steven C Ghivizzani; Mary Chester Wasko; Matthew M Tomaino; Richard Kang; Thomas A Muzzonigro; Molly Vogt; Elaine M Elder; Theresa L Whiteside; Simon C Watkins; James H Herndon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

Review 5.  Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Biological drug use: US perspectives on indications and monitoring.

Authors:  J J Cush
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

7.  Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis.

Authors:  T Heiberg; A Finset; T Uhlig; T K Kvien
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

Review 8.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans.

Authors:  Matthew T Haren; Theodore K Malmstrom; Douglas K Miller; Ping Patrick; H M Perry; Margaret M Herning; William A Banks; John E Morley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-10-07       Impact factor: 6.053

Review 10.  A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Tracy J Doyle; Joyce S Lee; Paul F Dellaripa; James A Lederer; Eric L Matteson; Aryeh Fischer; Dana P Ascherman; Marilyn K Glassberg; Jay H Ryu; Sonye K Danoff; Kevin K Brown; Harold R Collard; Ivan O Rosas
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.